LDS/Medical Tests/Insulin-Like Growth Factor I (IGF1)

Insulin-Like Growth Factor I (IGF1)

Insulin-like growth factor 1 (IGF-1), also known as somatomedin C, is a small polypeptide hormone similar to proinsulin, an insulin progenitor. IGF-1 is produced mainly by the liver; however, some peripheral tissues produce IGF-1 in response to growth hormone (GH). The main function of IGF-1 is to mediate the growth-promoting effects of human GH in peripheral tissues. Its action is insulin-like, especially in fat and muscle. In addition, it also stimulates collagen and protein synthesis. IGF-1 circulates in the body mostly bound to insulin-like growth factor binding proteins (IGFBP). Concentration of IGF-1 is regulated by genetic factors, nutrient intake, GH, Insulin-like growth factor binding proteins, insulin, T4, cortisol, sex hormones and age.

Testing for IGF-1 is used for evaluation of growth activity, the responsiveness of peripheral tissues to changes in GH secretion, and for the diagnosis of related disorders. Since blood levels of IGF-1 are stable through the day, IGF-1 is a sensitive test for acromegaly. Acromegaly is a disorder that results when the pituitary gland produces excess growth hormone. Both IGF-1 and GH are increased in acromegaly. Normal IGF-1 levels rule out active acromegaly. Values may be normal, however, in GH-deficient patients with hyperprolactinemia or craniopharyngioma. This test is also used to evaluate hypopituitarism and hypothalamic lesions in children. IGF-1 is also very useful in monitoring GH treatment.

Low levels of IGF-1 are seen in malnutrition, pituitary dwarfism (short statue), hypopituitarism, Laron-type dwarfism (usually due to tissue resistance to GH), hypothyroidism, and cirrhosis of the liver.

  • Diagnosis of acromegaly
  • Growth hormone therapy treatment monitoring
  • As an aid in diagnosis of dwarfism

Increased in:

  • Acromegaly
  • GH treatment (such as in Laron-type dwarfism)
  • Some cancers

Decreased in:

  • Pituitary dwarfism
  • Hypopituitarism
  • Laron-type dwarfism (resistance to GH)
  • Malnutrition
  • Hypothyroidism
  • Liver cirrhosis
Age / Sex ng/mL or mg/L
1–2 yr Male 31–160
1–2 yr Female 11–206
3–6 yr Male 16–288
3–6 yr Female 70–316
7–10 yr Male 136–385
7–10 yr Female 123–396
11–12 yr Male 136–440
11–12 yr Female 191–462
13–14 yr Male 165–616
13–14 yr Female 286–660
15–18 yr Male 134–836
15–18 yr Female 152–660
19–25 yr Male 202–433
19–25 yr Female 231–550
Adult 26–85 yr 135–449

Electrochemiluminescence immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).

Serum (Red) or Plasma EDTA (Lavender),Heparin (Green).

Separate serum or Plasma and keep frozen.
SST is not acceptable. Freeze immediately.

Stability

  • Ambient: 48 hours
  • Refrigerated: 5 days
  • Frozen: 30 days
Growth Hormone, Insulin-Like Growth Factor Binding Protein (IGFBP), Cortisol, Insulin levels, C-peptide.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login